Madrigal Pharmaceuticals, Inc.: shareholders and insiders

MDGLNASDAQHealthcare · Pharmaceutical Preparations

Price

$398.08

November 18, 2026Market cap $11.6B

What Ploutos Investor adds for Madrigal Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 6, 2026, from their own Form 4 filings.

13 Form 4s

Bought on the market

$35M

1 person

Sold on the market

$69M

8 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan89%
  • The rest11%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $35M by 1 person·sold $41M by 8 people

  • 2025: no buys, sold $29M by 5 people
  • 2026: bought $35M by 1 person, sold $41M by 8 people
  • Nov 6, 2026Baker Bros. Advisors LpDirector
    Kind
  • Nov 6, 2026Baker Bros. Advisors LpDirector
    Kind
  • Nov 6, 2026Baker Bros. Advisors LpDirector
    Kind
  • Nov 6, 2026Shannon T KelleyGeneral Counsel
    Kind10b5-1
  • Nov 4, 2026Baker Bros. Advisors LpDirector
    Kind
  • Nov 4, 2026Baker Bros. Advisors LpDirector
    Kind
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 11, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1
  • Sep 9, 2026William John SiboldPresident and CEO
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by MDGL's officers and directors from 2007 up to November 18, 2025, 19 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%3 On a 13DNov 6, 2026 Latest filing
  • Baker Bros. Advisors LPwith 3 more persons
    Share of class9.99%
  • Janus Henderson Group
    Share of class8.80%
  • Paul A Friedman, M.D.
    Share of class7.80%
  • Rebecca Taub, M.D.
    Share of class7.80%
  • Paulson
    Share of class6.10%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Baker Bros. Advisors LP10.0%From the filing of Nov 6, 2026

    Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: This Amendment No. 5 is being filed to report the acquisition of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent…

    From the filing of Nov 6, 2026
  • Paul A Friedman, M.D.7.8%From the filing of Dec 12, 2025

    No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.

    From the filing of Dec 12, 2025
  • Rebecca Taub, M.D.7.8%From the filing of Dec 12, 2025

    No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer.

    From the filing of Dec 12, 2025
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • BlackRock, Inc.4.60%Jul 29, 202613G/A
  • The Vanguard Group0.00%Mar 27, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Bridgewater (Dalio)
    In the quarter
  • Point72 (Cohen)
    In the quarter
  • AQR Capital
    In the quarter×40.2
  • Renaissance Technologies
    In the quarter-3.7%
  • Citadel Advisors (Griffin)
    In the quarter-85%
  • D.E. Shaw
    In the quarter-15%
  • Millennium Mgmt (Englander)
    In the quarter-90%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 7.50% of its shares outstanding were held short, -8.4% since the report before.

Shares held short
2.19M
7.50%
Since the report before2.40M on Sep 30, 2026
-8.4%
7.2
303.1K
More days to cover thanof 4,578 US-listed companies with enough volume
79%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 3.41M
  • Nov 15, 2023: Shares held short 3.46M
  • Nov 30, 2023: Shares held short 3.47M
  • Dec 15, 2023: Shares held short 3.07M
  • Dec 29, 2023: Shares held short 3.25M
  • Jan 12, 2024: Shares held short 3.31M
  • Jan 31, 2024: Shares held short 3.14M
  • Feb 15, 2024: Shares held short 3.39M
  • Feb 29, 2024: Shares held short 3.46M
  • Mar 15, 2024: Shares held short 3.26M
  • Mar 28, 2024: Shares held short 3.36M
  • Apr 15, 2024: Shares held short 3.41M
  • Apr 30, 2024: Shares held short 3.98M
  • May 15, 2024: Shares held short 4.17M
  • May 31, 2024: Shares held short 5.23M
  • Jun 14, 2024: Shares held short 4.43M
  • Jun 28, 2024: Shares held short 4.08M
  • Jul 15, 2024: Shares held short 4.11M
  • Jul 31, 2024: Shares held short 3.68M
  • Aug 15, 2024: Shares held short 3.75M
  • Aug 30, 2024: Shares held short 3.76M
  • Sep 13, 2024: Shares held short 3.73M
  • Sep 30, 2024: Shares held short 3.86M
  • Oct 15, 2024: Shares held short 4.05M
  • Oct 31, 2024: Shares held short 4.53M
  • Nov 15, 2024: Shares held short 4.43M
  • Nov 29, 2024: Shares held short 4.28M
  • Dec 13, 2024: Shares held short 4.73M
  • Dec 31, 2024: Shares held short 4.11M
  • Jan 15, 2025: Shares held short 4.08M
  • Jan 31, 2025: Shares held short 3.98M
  • Feb 14, 2025: Shares held short 3.80M
  • Feb 28, 2025: Shares held short 3.75M
  • Mar 14, 2025: Shares held short 4.09M
  • Mar 31, 2025: Shares held short 4.00M
  • Apr 15, 2025: Shares held short 4.03M
  • Apr 30, 2025: Shares held short 4.10M
  • May 15, 2025: Shares held short 4.00M
  • May 30, 2025: Shares held short 3.89M
  • Jun 13, 2025: Shares held short 4.15M
  • Jun 30, 2025: Shares held short 3.97M
  • Jul 15, 2025: Shares held short 3.79M
  • Jul 31, 2025: Shares held short 3.98M
  • Aug 15, 2025: Shares held short 3.79M
  • Aug 29, 2025: Shares held short 4.05M
  • Sep 15, 2025: Shares held short 4.14M
  • Sep 30, 2025: Shares held short 3.72M
  • Oct 15, 2025: Shares held short 3.69M
  • Oct 31, 2025: Shares held short 3.74M
  • Nov 14, 2025: Shares held short 3.79M
  • Nov 28, 2025: Shares held short 3.72M
  • Dec 15, 2025: Shares held short 3.72M
  • Dec 31, 2025: Shares held short 3.71M
  • Jan 15, 2026: Shares held short 3.86M
  • Jan 30, 2026: Shares held short 3.98M
  • Feb 13, 2026: Shares held short 3.62M
  • Feb 27, 2026: Shares held short 3.74M
  • Mar 13, 2026: Shares held short 3.93M
  • Mar 31, 2026: Shares held short 3.91M
  • Apr 15, 2026: Shares held short 4.01M
  • Apr 30, 2026: Shares held short 3.85M
  • May 15, 2026: Shares held short 3.90M
  • May 29, 2026: Shares held short 3.82M
  • Jun 15, 2026: Shares held short 3.78M
  • Jun 30, 2026: Shares held short 3.53M
  • Jul 15, 2026: Shares held short 2.06M
  • Jul 31, 2026: Shares held short 1.97M
  • Aug 14, 2026: Shares held short 2.03M
  • Aug 31, 2026: Shares held short 2.24M
  • Sep 15, 2026: Shares held short 2.25M
  • Sep 30, 2026: Shares held short 2.40M
  • Oct 15, 2026: Shares held short 2.19M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading56.4% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 56.4% of the shares in the reported trades were short sales, against 44.6% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
56.4%
The 14 beforeOct 12, 2026 – Oct 29, 2026
44.6%
Change
+11.8 pts
Short sales a dayon average, of 365.0K shares
206.0K
More than atof 3,656 US-listed companies, same days
72%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 29.7%
  • Oct 13, 2026: Short sales 43.6%
  • Oct 14, 2026: Short sales 50.7%
  • Oct 15, 2026: Short sales 46.7%
  • Oct 16, 2026: Short sales 59.2%
  • Oct 19, 2026: Short sales 49.1%
  • Oct 20, 2026: Short sales 50.8%
  • Oct 21, 2026: Short sales 60.6%
  • Oct 22, 2026: Short sales 41.2%
  • Oct 23, 2026: Short sales 42.8%
  • Oct 26, 2026: Short sales 40.7%
  • Oct 27, 2026: Short sales 42.7%
  • Oct 28, 2026: Short sales 32.8%
  • Oct 29, 2026: Short sales 39.8%
  • Oct 30, 2026: Short sales 51.5%
  • Nov 2, 2026: Short sales 61.2%
  • Nov 3, 2026: Short sales 52.7%
  • Nov 4, 2026: Short sales 64%
  • Nov 5, 2026: Short sales 57.4%
  • Nov 6, 2026: Short sales 46.5%
  • Nov 9, 2026: Short sales 48.1%
  • Nov 10, 2026: Short sales 50.6%
  • Nov 11, 2026: Short sales 50.6%
  • Nov 12, 2026: Short sales 67.4%
  • Nov 13, 2026: Short sales 75.2%
  • Nov 16, 2026: Short sales 70.9%
  • Nov 17, 2026: Short sales 56.1%
  • Nov 18, 2026: Short sales 47.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

12.91M Insiders' shares56.29% Of the company
  • Baker Bros. Advisors LpDirector
    Directly451.0K
  • Baker Bros. Advisors (GP) LLCDirector
    Directly–
  • Felix BakerDirector
    Directly–
  • 667, L.p.Director
    Directly–
  • Julian BakerDirector
    Directly–
  • Baker Brothers Life Sciences LPDirector
    Directly–
  • Rebecca TaubDirector
    Directly1.11M
  • Fred B CravesDirector
    Directly355.9K
  • William John SiboldPresident and CEO
    Directly202.8K
  • Paul A FriedmanDirector
    Directly200.3K
  • Richard S LevyDirector
    Directly22.5K
  • Brian Joseph LynchSVP and General Counsel
    Directly15.0K
  • Mardi DierEVP and CFO
    Directly12.9K
  • Carole HuntsmanChief Commercial Officer
    Directly12.7K
  • Robert E. WaltermireSenior VP, Chief Pharma Dev.
    Directly10.9K
  • Shannon T KelleyGeneral Counsel
    Directly10.4K
  • David SoergelChief Medical Officer
    Directly10.0K
  • Kenneth BateDirector
    Directly8,896
  • James M DalyDirector
    Directly3,081
  • Jacqualyn A FouseDirector
    Directly1,551
  • Daniel J. BrennanDirector
    Directly1,371
  • John C ReedDirector
    Directly647

A lower bound: it counts only the 22 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

26 ETFs holding it1.06% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund1.06%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.91%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.68%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.30%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.28%
  • IWPiShares Russell Mid-Cap Growth ETF
    Weight in the fund0.26%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.21%
  • SCHMSchwab U.S. Mid-Cap ETF
    Weight in the fund0.19%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund0.14%
  • VBVanguard Small-Cap Index Fund
    Weight in the fund0.12%

26 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

413 Managers, Q2 2026$12.7B Value of their positions
  • Q3 2025: Managers 354
  • Q4 2025: Managers 389
  • Q1 2026: Managers 382
  • Q2 2026: Managers 413

Institutional investors by quarter

The fund managers holding MDGL, quarter by quarter, from Q2 2016 to Q2 2025, 37 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 413 managers held 23.71M shares, worth $12.7B. During the quarter 78 opened a position, 47 closed one, 141 added and 129 trimmed.

The largest holders, Q2 2026

  • Baker Bros. Advisors
    In the quarter
  • Rtw Investments
    In the quarter
  • Jupiter Topco
    In the quarter
  • Avoro Capital Advisors
    In the quarter+0.8%
  • Paulson
    In the quarter-3.7%
  • BlackRock
    In the quarter-23%
  • Vanguard Capital Management
    In the quarter+1.0%
  • Wellington Management Group
    In the quarter+19%
  • Vanguard Portfolio Management
    In the quarter-7.1%
  • State Street
    In the quarter-14%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Madrigal Pharmaceuticals's filings show?

Who buys and sells is one part of Madrigal Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MDGL's shareholders

Didn't find what you were looking for?

Ask us
Have MDGL's insiders bought or sold?

From Jun 1, 2026 to Nov 6, 2026 Madrigal Pharmaceuticals's insiders bought $35M and sold $8.9M of shares on the market. 81% of the sales were under set 10b5-1 plans.

Which well-known managers hold MDGL?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $321M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.